A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
Public ClinicalTrials.gov record NCT05061693. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
Study identification
- NCT ID
- NCT05061693
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 146 participants
Conditions and interventions
Conditions
Interventions
- INCB054707 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 3, 2021
- Primary completion
- Aug 10, 2023
- Completion
- Feb 27, 2024
- Last update posted
- Jul 10, 2025
2021 – 2024
United States locations
- U.S. sites
- 23
- U.S. states
- 12
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site US010 | Phoenix | Arizona | 85006 | — |
| Investigative Site US024 | Phoenix | Arizona | 85018 | — |
| Investigative Site US001 | Fountain Valley | California | 92708 | — |
| Investigative Site US014 | Sacramento | California | 95816 | — |
| Investigative Site US019 | Fort Lauderdale | Florida | 33308 | — |
| Investigative Site US016 | Miami | Florida | 33175 | — |
| Investigative Site US013 | Miramar | Florida | 33027 | — |
| Investigative Site US009 | Tampa | Florida | 33609-2231 | — |
| Investigative Site 1071320 | Newnan | Georgia | 30263 | — |
| Investigative Site US008 | Plainfield | Indiana | 46168 | — |
| Investigative Site US011 | South Bend | Indiana | 46617 | — |
| Investigative Site US003 | Baltimore | Maryland | 21287 | — |
| Investigative Site US017 | Troy | Michigan | 48084 | — |
| Investigative Site US006 | Saint Joseph | Missouri | 64506 | — |
| Investigative Site US004 | Portsmouth | New Hampshire | 03801 | — |
| Investigative Site US023 | Athens | Ohio | 45701 | — |
| Investigative Site US002 | Dublin | Ohio | 43016 | — |
| Investigative Site US012 | Gahanna | Ohio | 43230 | — |
| Investigative Site US022 | Murfreesboro | Tennessee | 37130 | — |
| Investigative Site US021 | Arlington | Texas | 76011 | — |
| Investigative Site US005 | Austin | Texas | 78745 | — |
| Investigative Site US018 | Dallas | Texas | 75231 | — |
| Investigative Site US007 | Houston | Texas | 77004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05061693, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05061693 live on ClinicalTrials.gov.